Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Cytotherapy|October 13, 2018
Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cellsSergey N Zolov, Skyler P Rietberg, Challice L Bonifant
American Journal of Physiology. Lung Cellular and Molecular Physiology|September 18, 2016
Protein phosphatase 2A activation attenuates inflammation in murine models of acute lung injuryWalker M McHugh, William W Russell, Andrew J Fleszar, et al.
Nature Medicine|April 18, 2018
Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomasChristopher W Mount, Robbie G Majzner, Shree Sundaresh, et al.
Nature|October 22, 2020
Immune receptor inhibition through enforced phosphatase recruitmentRicardo A Fernandes, Leon Su, Yoko Nishiga, et al.
Nature|March 8, 2023
Co-opting signalling molecules enables logic-gated control of CAR T cellsAidan M Tousley, Maria Caterina Rotiroti, Louai Labanieh, et al.
Cancer Discovery|March 21, 2020
Tuning the Antigen Density Requirement for CAR T-cell ActivityRobbie G Majzner, Skyler P Rietberg, Elena Sotillo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2019
CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain TumorsRobbie G Majzner, Johanna L Theruvath, Anandani Nellan, et al.
Nature|November 13, 2024
Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomasMichelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Medrxiv : the Preprint Server for Health Sciences|July 9, 2024
Sequential intravenous and intracerebroventricular GD2-CAR T-cell therapy for H3K27M-mutated diffuse midline gliomasMichelle Monje, Jasia Mahdi, Robbie Majzner, et al.
Pageof 2